We use a few cookies

Essential cookies keep the library working. With your permission, we'd also like to use analytics to see what's useful and improve the experience. Read our Privacy Policy or Cookie Policy.

Skip to main content
Home/e-Resources/Medical Sciences/Albumin- Bilirubin Score as a Non-Invasive Serum Biomarker for Advanced Liver Fibrosis and Cirrhosis in Egyptian Patients with Chronic Hepatitis C Infection: A Case-Control Study
PeriodicalsMedical Sciences

Albumin- Bilirubin Score as a Non-Invasive Serum Biomarker for Advanced Liver Fibrosis and Cirrhosis in Egyptian Patients with Chronic Hepatitis C Infection: A Case-Control Study

Checking your access to this record.

Abstract & Overview

Background: In many health systems, primary care is the main source of health care services. Liver cirrhosis is a silent disease that causes no signs or symptoms until decompensation occurs. Therefore, a simple and readily accessible tool for predicting advanced liver fibrosis and cirrhosis is needed to aid general practitioners in primary care settings. Aim: To explore the predictive performance of Albumin Bilirubin (ALBI) score as a non-invasive serum biomarker for advanced liver fibrosis and cirrhosis. Methods: This case-control study was conducted at Zagazig University Hospitals, Egypt, and comprised 400 participants divided into two equal groups. Group (I): 200 chronic HCV patients with advanced liver fibrosis and cirrhosis [F3-F4], and Group (II): 200 healthy controls. ALBI score was calculated for all study participants. Results: The AUROC for the ALBI score was 0.832 (95% CI: 0.787-0.872) (p-value <0.001), sensitivity= 74.8%, specificity= 80.2%, PPV= 86.8%, NPV =64.6%, and positive likelihood ratio=3.77. The cut-off value to differentiate chronic HCV patients with advanced liver fibrosis and cirrhosis from healthy controls was -2.781. Sub-group analysis of chronic HCV cases showed a statistically significant difference in the mean ALBI score between (F3) and (F4) cases (p-value<0.0001) with an AUROC of 0.654 (p-value=0.028). Conclusion: ALBI score is reliable for predicting advanced liver fibrosis and cirrhosis and could be valuable in primary care.

Cite this record

Dina Ali, Mohamed Atef AlMoslemany, Osama Mohamed, Khaled Raafat (2022). Albumin- Bilirubin Score as a Non-Invasive Serum Biomarker for Advanced Liver Fibrosis and Cirrhosis in Egyptian Patients with Chronic Hepatitis C Infection: A Case-Control Study. african journal of gastroenterology and hepatology, 5(2), 32–47. https://doi.org/10.21608/ajgh.2022.173503.1019

Copy in another style

Ali, D., AlMoslemany, M. A., Mohamed, O., & Raafat, K. (2022). Albumin- Bilirubin Score as a Non-Invasive Serum Biomarker for Advanced Liver Fibrosis and Cirrhosis in Egyptian Patients with Chronic Hepatitis C Infection: A Case-Control Study. african journal of gastroenterology and hepatology, 5(2), 32–47. https://doi.org/10.21608/ajgh.2022.173503.1019
Author names are used as deposited, so check their order before you submit.

Metadata is harvested from open-access indexes and can be incomplete. Check a citation against the published version before relying on it — see our open access & attribution policy.